ADA, a fully humanized monoclonal antibody specifically targeting TNF-α, has been proven to be a feasible and prospective option for the treatment of non-infective uveitis and has been approved by the FDA and National Medical Products Administration (NMPA) in the treatment of non-infectious uveitis in 2016 and 2020, respectively. The gene discussed is TNF; the disease is uveitis.